Advertisement

Complement regulation in human atherosclerotic coronary lesions

Immunohistochemical evidence that C4b-binding protein negatively regulates the classical complement pathway, and that C5b-9 is formed via the alternative complement pathway

      Abstract

      Objective

      The complement system is activated in human atherosclerotic lesions and may hence aggravate local inflammation. We studied the presence and localization of C4b-binding protein (C4bp), the major inhibitor of the classical complement pathway, in human atherosclerotic lesions in relation to complement activation products and protein S, which circulates in complex with C4bp.

      Methods and results

      Immunohistochemistry of human coronary arteries showed C4bp to be virtually absent in normal arteries but present in early and advanced atherosclerotic lesions. In the lesions, C4bp is associated with proteoglycans, and affinity chromatography showed that C4bp interacts with human arterial proteoglycans. Areas containing C4bp also contained IgM and C4 suggesting that C4bp is involved in the regulation of the classical complement pathway. However, C5b-9 was virtually absent in these areas but, instead, colocalized with properdin deeper in the intima, suggesting that C5b-9 is formed by the alternative complement pathway. A fraction of C4bp was associated with protein S and apoptotic cells.

      Conclusions

      The results indicate that C4bp regulates the classical complement pathway in human atherosclerotic lesions. Thus, unlike the alternative pathway, the classical complement pathway does not generate C5b-9, but is likely to be involved in the clean-up of apoptotic cells and cell debris in the arterial intima.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Libby P.
        • Ridker P.M.
        • Maseri A.
        Inflammation and atherosclerosis.
        Circulation. 2002; 105: 1135-1143
        • Miller G.W.
        • Nussenzweig V.
        A new complement function: solubilization of antigen–antibody aggregates.
        Proc Natl Acad Sci USA. 1975; 72: 418-422
        • Fernandez N.
        • Renedo M.
        • Alonso S.
        • et al.
        Release of arachidonic acid by stimulation of opsonic receptors in human monocytes: the FcgammaR and the complement receptor 3 pathways.
        J Biol Chem. 2003; 278: 52179-52187
        • Korb L.C.
        • Ahearn J.M.
        C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited.
        J Immunol. 1997; 158: 4525-4528
        • Prodeus A.P.
        • Goerg S.
        • Shen L.M.
        • et al.
        A critical role for complement in maintenance of self-tolerance.
        Immunity. 1998; 9: 721-731
      1. Frostegård J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 2005.

        • Buono C.
        • Come C.E.
        • Witztum J.L.
        • et al.
        Influence of C3 deficiency on atherosclerosis.
        Circulation. 2002; 105: 3025-3031
        • Schmiedt W.
        • Kinscherf R.
        • Deigner H.P.
        • et al.
        Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits.
        Arterioscler Thromb Vasc Biol. 1998; 18: 1790-1795
        • Bhakdi S.
        • Dorweiler B.
        • Kirchmann R.
        • et al.
        On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety.
        J Exp Med. 1995; 182: 1959-1971
        • Torzewski M.
        • Klouche M.
        • Hock J.
        • et al.
        Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion.
        Arterioscler Thromb Vasc Biol. 1998; 18: 369-378
        • Vlaicu R.
        • Rus H.G.
        • Niculescu F.
        • et al.
        Immunoglobulins and complement components in human aortic atherosclerotic intima.
        Atherosclerosis. 1985; 55: 35-50
        • Reynolds G.D.
        • Vance R.P.
        C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas.
        Arch Pathol Lab Med. 1987; 111: 265-269
        • Rolph M.S.
        • Zimmer S.
        • Bottazzi B.
        • et al.
        Production of the long pentraxin PTX3 in advanced atherosclerotic plaques.
        Arterioscler Thromb Vasc Biol. 2002; 22: e10-e14
        • Yasojima K.
        • Schwab C.
        • McGeer E.G.
        • et al.
        Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques.
        Arterioscler Thromb Vasc Biol. 2001; 21: 1214-1219
        • Scharfstein J.
        • Ferreira A.
        • Gigli I.
        • et al.
        Human C4-binding protein. I. Isolation and characterization.
        J Exp Med. 1978; 148: 207-222
        • Gigli I.
        • Fujita T.
        • Nussenzweig V.
        Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.
        Proc Natl Acad Sci USA. 1979; 76: 6596-6600
        • Blom A.M.
        • Kask L.
        • Dahlback B.
        CCP1-4 of the C4b-binding protein alpha-chain are required for factor I mediated cleavage of complement factor C3b.
        Mol Immunol. 2003; 39: 547-556
        • Villoutreix B.O.
        • Blom A.M.
        • Webb J.
        • et al.
        The complement regulator C4b-binding protein analyzed by molecular modeling, bioinformatics and computer-aided experimental design.
        Immunopharmacology. 1999; 42: 121-134
        • Stary H.C.
        • Chandler A.B.
        • Glagov S.
        • et al.
        A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association.
        Circulation. 1994; 89: 2462-2478
        • Stary H.C.
        • Chandler A.B.
        • Dinsmore R.E.
        • et al.
        A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association.
        Arterioscler Thromb Vasc Biol. 1995; 15: 1512-1531
        • Öörni K.
        • Pentikäinen M.O.
        • Annila A.
        • et al.
        Oxidation of low density lipoprotein particles decreases their ability to bind to human aortic proteoglycans. Dependence on oxidative modification of the lysine residues.
        J Biol Chem. 1997; 272: 21303-21311
        • Trouw L.A.
        • Nilsson S.C.
        • Goncalves I.
        • et al.
        C4b-binding protein binds to necrotic cells and DNA, limiting DNA release and inhibiting complement activation.
        J Exp Med. 2005; 201: 1937-1948
        • Rezende S.M.
        • Simmonds R.E.
        • Lane D.A.
        Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex.
        Blood. 2004; 103: 1192-1201
        • Webb J.H.
        • Blom A.M.
        • Dahlback B.
        Vitamin K-dependent protein S localizing complement regulator C4b-binding protein to the surface of apoptotic cells.
        J Immunol. 2002; 169: 2580-2586
        • Kockx M.M.
        Apoptosis in the atherosclerotic plaque: quantitative and qualitative aspects.
        Arterioscler Thromb Vasc Biol. 1998; 18: 1519-1522
        • Vlaicu R.
        • Niculescu F.
        • Rus H.G.
        • et al.
        Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque.
        Atherosclerosis. 1985; 57: 163-177
        • Meri S.
        • Koistinen V.
        • Miettinen A.
        • et al.
        Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis.
        J Exp Med. 1992; 175: 939-950
        • Laine P.
        • Pentikäinen M.O.
        • Wurzner R.
        • et al.
        Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction.
        Am J Cardiol. 2002; 90: 404-408
        • Oksjoki R.
        • Jarva H.
        • Kovanen P.T.
        • et al.
        Association between complement factor h and proteoglycans in early human coronary atherosclerotic lesions: implications for local regulation of complement activation.
        Arterioscler Thromb Vasc Biol. 2003; 23: 630-636
        • Yasojima K.
        • Schwab C.
        • McGeer E.G.
        • et al.
        Generation of C-reactive protein and complement components in atherosclerotic plaques.
        Am J Pathol. 2001; 158: 1039-1051
        • Blom A.M.
        • Villoutreix B.O.
        • Dahlback B.
        Complement inhibitor C4b-binding protein-friend or foe in the innate immune system?.
        Mol Immunol. 2004; 40: 1333-1346
        • Anderson H.A.
        • Maylock C.A.
        • Williams J.A.
        • et al.
        Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells.
        Nat Immunol. 2003; 4: 87-91
        • Kask L.
        • Trouw L.A.
        • Dahlback B.
        • et al.
        The C4b-binding protein-protein S complex inhibits the phagocytosis of apoptotic cells.
        J Biol Chem. 2004; 279: 23869-23873
        • Persson L.
        • Boren J.
        • Robertson A.K.
        • et al.
        Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E−/− low-density lipoprotein receptor−/− mice 1.
        Arterioscler Thromb Vasc Biol. 2004; 24: 1062-1067
        • Nityanand S.
        • Truedsson L.
        • Mustafa A.
        • et al.
        Circulating immune complexes and complement C4 null alleles in patients in patients operated on for premature atherosclerotic peripheral vascular disease.
        J Clin Immunol. 1999; 19: 406-413